Delivery Order SPE2DB20D9331-SPE2DB25FL1G9

Award Date 5/19/25
Potential Completion Date 6/10/25
Potential Value $5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $3,210.96 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of TISSUEBLUE 0.025% SYRINGE 0.5ML, a specialized pharmaceutical product, with a period of performance through December 20, 2024. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,654.44 firm fixed-price delivery order contract is for the provision of TISSUEBLUE 0.025% SYRINGE 0.5ML, a specialized pharmaceutical product. The contract does not have a set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
This federal contract award, with ID SPE2DB20D9331 and SPE2DB23FL1M2, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,088.56 firm fixed-price delivery order is for the supply of TISSUEBLUE 0.025% SYRINGE 0.5ML, a pharmaceutical product, with a completion date of September 21, 2023. This award is part of a larger indefinite delivery contract (IDC) valued at up to...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $4,816.44 under the Defense Logistics Agency's (DLA) SPE2DB indefinite delivery contract (IDC). The IDC, valued at up to $499,999,999, covers a comprehensive range of pharmaceutical products and medical supplies to fulfill the recurring medical needs of Department of Defense (DoD) healthcare facilities worldwide. This delivery order,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,249.10 firm fixed-price delivery order is for the supply of TISSUEBLUE 0.025% SYRINGE 0.5ML, a pharmaceutical product, with an ultimate completion date of November 16, 2022. DMS Pharmaceutical Group is the prime contractor and there is no set-aside designation for this award. This delivery order is part of a larger...
This federal contract award (SPE2DX15D9168|SPE2DX24F6XCQ) was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business in Park Ridge, Illinois. The $4,013.70 firm fixed-price delivery order is for the supply of TISSUEBLUE 0.025% SYRINGE 0.5ML and does not have a set-aside designation. The award is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (4600082013) with the DLA, worth up to $4,999,999 through 2025, which...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $4,013.70 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 0.5 mL syringes containing 0.025% Tissue Blue solution. This order is issued against DMS Pharmaceutical's indefinite delivery contract SPE2DB valued at up to $4,999,999 through 2025, which enables DLA to procure a broad range of pharmaceutical products for...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,210.96, is for the supply of a pharmaceutical product, Tissueblue 0.025% Syringe 0.5ML, to support the recurring medical supply needs of military health facilities. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) awarded to...
This federal contract award, valued at $3,210.96, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract is for the delivery of 0.5 mL syringes containing 0.025% tissueblue solution, a medical product used in various healthcare applications. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
This federal contract award is for a delivery order from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a firm fixed-price ceiling value of $4,430.80 and covers the delivery of medical supplies including pharmaceutical products like injections, tablets, creams, and specialty medications. The contract is part of a larger indefinite delivery contract (IDC) with DMS...
  • SPE2DB20D9331
    Indefinite Delivery Contract
  • SPE2DB20D9331-SPE2DB25FL1G9
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $4,963.32 firm fixed-price delivery order is for the supply of TISSUEBLUE 0.025% SYRINGE 0.5ML medical products. The contract has an ultimate completion date of June 10, 2025.

DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide. This positioning establishes DMS Pharmaceutical Group as a critical supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

The contract award did not utilize any set-aside designations. The company's status as a woman-owned small business allows it to compete effectively in federal procurement markets for these types of pharmaceutical product deliveries.

Generated 8/18/25, 9:50 AM